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We reported a relevant activity of the combination between sorafenib and octreotide long-acting release (LAR) in advanced
hepatocellular carcinoma (HCC) patients. In this work, we have studied if oxidative stress in both serum and peripheral blood
mononuclear cells (PBMC) and pERK activation status in PBMC could be predictive of response. In the 20 responsive patients,
the decrease of reactive oxygen species levels was already detectable after 10 days (T10) from the beginning of sorafenib
administration, and this effect was enhanced by the combined treatment with sorafenibþoctreotide LAR (T21). This effect
correlated with the modulation of superoxide dismutase (SOD) activity (physiological scavenger of O
2 ) and of serum nitric
oxide (NO) levels. Sorafenib alone induced an increase of about 40% of NO levels and of about two-fold of SOD activity in
responsive patients, and both effects were signiﬁcantly potentiated by the combined treatment. We found a gradual reduction of
Erk1/2activity,asevaluatedbycytoﬂuorimetricanalysis,in15responsivepatientsreachingabout50%maximaldecreaseatT21.
On the other hand, in 17 resistant patients, Erk1/2 activity was about 80% increased at T21. The determination of both the
oxidative stressstatusandpERK activity inPBMC has highvalue inthe predictionofresponsetosorafenibþoctreotidetherapy
in HCC patients.
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Hepatocellular carcinoma (HCC) is the ﬁfth most common
cancer in the world, and the third most common cause of
cancer-related death. The number of new cases is estimated
to be 564000 per year, including 398000 in men and 166000
inwomen.Itaccountsforupto75–85%ofprimarylivercancer
in the United States and for over 90% in high-risk areas. It has
predominantlyaffectedthosein developingcountries,suchas
sub-SaharanAfrica,China,Taiwan,Korea,orVietnam,where
the hepatitis B virus (HBV) is endemic.
1,2 On the other hand,
HCC is relatively rare in Europe.
3 In Italy, the incidence and
mortality rates are at a median frequency, compared with
other populations, and it represents the seventh cause of
death from tumor, with about 5000 deaths per year.
4,5 In the
Unites States, the incidence is increased.
6 In the majority of
thecases,thereisunderlyingcirrhosis,mainlycausedbyHBV
and hepatitis C viruses (HCV).
1,7
Ablative therapies, surgical resection or liver transplanta-
tionaretheﬁrst-linetreatmentforpatientsaffectedwithHCC.
8
Nonetheless, advanced tumor stage and poor liver function
preclude the majority of patients from these surgical interven-
tions. In addition to this obstacle, transplantation is indicated
only for early small HCC, and its application is limited by the
availability of liver grafts.
9 Therefore, there is an urgent need
to develop an effective systemic therapy for patients with
advanced HCC.
10
In the last years, many advances in the knowledge of the
molecular mechanisms that govern tumor development and
progression have been made.
11 More recently, single agent
sorafenib (Bayer 43-9006; Nexavar, Bayer AG Inc., Leverkusen,
Germany), a putative multi-targeted kinase inhibitor, has
shown to prolong the overall survival (OS) of patients with
advanced HCC in the pivotal phase III Sorafenib HCC
Assessment Randomized Protocol (SHARP) and Oriental
study.
9 Currently, sorafenib is the only approved targeted
therapy for patients with advanced HCC.
Sorafenib is an oral multikinase inhibitor able to block both
tyrosine kinase and serin-threonin-kinase activities. Mutation
or over-activation of related components in the Raf/MAPK
cascade would lead to acceleration of cell proliferation and
extension of survival, thus contributing to human oncogen-
esis.
12 This pathway has been implicated in the molecular
pathogenesis of HCC for three principal reasons: (i) the Ras
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13 (ii) the
over-expression of its substrate Raf kinase occurs in most
HCCs;
14 (iii) a variety of upstream growth factors, such as
epidermal growth factor, vascular endothelial growth factor
(VEGF), platelet-derived growth factor-b (PDGF) and trans-
forming growth factor-a, which are generally overexpressed in
HCC, can activate this pathway through binding their receptor
tyrosine kinases.
15,16 Sorafenib blocks tumor cell proliferation
and tumor angiogenesis, and increases the rate of apoptosis
in a wide range of tumor models by targeting the Raf/MAPK-
and VEGF-mediated pathways.
16,17
The combination of sorafenib with agents active in the
control of the HCC-derived symptoms could be useful in the
clinical strategy of HCC.
Differential somatostatin receptor subtypes (SSTR 1, 2, 3
and 5) are expressed in HCC.
18 Analogs of somatostatin,
such as octreotide, which display high binding afﬁnity to
SSTR2 and lower afﬁnity to SSTR5 and SSTR3 (afﬁnity rank
order: SSTR24SSTR54SSTR3) are efﬁcacious in the
treatment of neuroendocrine tumors and exhibit only mild
toxicity.
19
Octreotide long-acting release (LAR) is a formulation of
octreotide encapsulated into microspheres of the biodegrad-
able glucose star polymer.
20 This synthetic version of
somatostatin differs from the latter for the prolonged half-life
that allows to administer the drug every 28 days to obtain
active plasmatic concentrations.
As somatostatin, octreotide reduces the release of growth
factors and inhibits neo-angiogenesis. Octreotide was pre-
viously used in HCC patients with conﬂicting results.
20,21
However, approximately 40% of patients respond to octreo-
tide with improved survival and an impressive quality of life.
22
We showed, in a previous study, that combination of
octreotide and radiofrequency ablation produced about 80%
of disease control and interesting meanOS (31.4 months) in a
series of advanced HCC patients.
23 Investigations on octreo-
tide in HCC are still ongoing also as National Cancer Institute
sponsored trials.
Onthe basisofthesepremises,our groupstarteda phaseII
multicenter study, based on the combination between
sorafenib and octreotide LAR (So.LAR protocol) in order to
assess its safety and activity in advanced HCC patients.
24 It
was recorded ﬁve partial responses (PR, 10%), 33 stationary
diseases (SD, 66%) and 12 progressions of disease (PD,
24%). Overall disease control rate (CRþPRþSD) was 76%.
In conclusion, the combination between So.LAR was active
and well tolerated in advanced HCC.
24
Continuous oxidative stress, which results from the
generation of reactive oxygen species (ROS) by environ-
mental factors or cellular mitochondrial dysfunction, has
recently been associated with the progression of chronic liver
diseases and hepatocarcinogenesis. On the other hand, a
distinctive pathological hallmark of HCC is a dramatic down-
regulation of oxidoreductase enzymes that constitute the
most important free radical scavenger systems represented
by catalase (CAT), superoxide dismutase (SOD) and
glutathione peroxidase.
25,26
The aim of this study was to deﬁne predictor parameter of
outcome to treatment in advanced HCC patients enrolled in
the phase II multicenter So.LAR study. Moreover, we have
investigated on the pharmaco-dynamic interference between
the two agents and the level of Erk activation that serves as a
surrogate of the activity of sorafenib.
In details, we have evaluated possible variations in
oxidative stress induced by treatment: we have assessed
the O
2  levels in peripheral blood mononuclear cells (PBMC)
and the nitric oxide (NO), SOD and CAT serum levels.
Moroever, we have evaluated the effects of treatment on
tyrosine phosphorylation levels of Erk-1/2 in PBMC.
Results
Modulation of intracellular levels of ROS. To evaluate the
intracellular levels of ROS, PBMC of 23 resistant and 20
responsive patients enrolled in the So.LAR study were
incubated with dihydroethidine followed by FACS analysis
of the oxidative product, ethidium, which emits red
ﬂuorescence. The mean ﬂuorescence intensity (MFI)
corresponds to ROS levels and to intracellular oxidative
stress due to superoxide anion (O
2 ) generation induced by
their presence.
In the patients responsive to treatment (SD), there was a
gradual time-dependent reduction of ﬂuorescence, indicating
a decrease of oxidative phenomena (Figure 1a). In detail, the
decrease of ROS levels was already detectable after 10 days
(T10) from the beginning of sorafenib administration (12%
mean reduction) and further decreased after 3 weeks (T21)
from the beginning of combined treatment with sorafenib
þoctreotide LAR (about 50%; Po0.005).
In patients resistant to treatment (PD), there was an
increase of about 60% of MFI after 10 (T10) and 21 (T21)
days from the beginning of treatment (Po0.004). In Figures
1b and c, two example of ROS determination in PBMC of a
resistant (B) and responsive (C) patient are reported, at
differenttimes oftreatment.Weobserved anoppositetrendof
intracellular ROS levels with a gradual increase of ﬂuores-
cence in the resistant patient (Figure 1b) and a gradual
decreaseofﬂuorescenceintherespondingpatient(Figure1c)
reaching a decrease of about 50% of MFI at T21 time. In
conclusion, in responding patients, we observed a reduction
of intracellular ROS levels that was evident after 21 days from
the beginning of the treatment (Cut-off: 19.3%).Moreover, the
addition of octreotide did not interfere with the reduction of
ROS induced by sorafenib, even potentiating its effect.
Modulation of SOD activation levels. On the basis of the
effect of treatment on intracellular oxidative stress regulation,
we have evaluated the levels of enzymatic activity of SOD
(physiological scavenger of ROS) in serum. We have
demonstrated that, in resistant patients, the treatment with
sorafenib for 10 days (T10) induced an about two-fold
increase of SOD activity, and this effect was signiﬁcantly
potentiated after the addition of octreotide LAR (Po0.002)
(Figure 2). Also in resistant patients, the treatment with
sorafenib for 10 days (T10) induced an about two-fold
increase of SOD activity, but it resumed to basal levels after
addition of octreotide LAR (T21) (Figure 2). These effects
were correlated to the modulation of intracellular ROS levels
described above.
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Cell Death and DiseaseIn the same patients, we have evaluated the levels of CAT
activity, recording no signiﬁcant changes in both resistant and
responding patients (data not shown).
These data suggestthatthedeterminationof serumSODat
T21 is useful to predict the sensitivity of the patients to the
combination therapy (cut off: 7.7U/ml).
Modulation of serum levels of NO. We have investigated if
the reduction of superoxide anions following the increase of
SOD activity in responding patients could be caused by the
increase in the serum levels of NO. We observed an increase
in NO levels of 75 and 50%, in resistant and responder
patients, respectively, after 3 days (T3) from the beginning of
treatment with sorafenib alone (Po0.005). Moreover, in
resistant patients, the NO levels resumed to basal levels from
T10 up to T21, whereas in responder patients NO was about
40% higher than basal levels in all the time points assessed
during the present study (Figure 3). These data suggest
again that the increase of NO levels recorded after 21 days
from the beginning of the treatment can be predictive of
response to therapy. Again, the addition of octreotide did not
modify the trend of NO levels in the responsive patients.
Modulation of Erk1/2 activity. Sorafenib inhibits the
phosphorylation of both Erk and Mek (downstream targets
of raf) and Erk1/2 activity can be considered a surrogate
Figure 2 Modulation of SOD activation levels. Variations of SOD serum levels
in 23 patients resistant to treatment (PD) and 20 patients responsive to the
treatment (SD) enrolled in the So.LAR study, using an enzyme spectrophotometric
assay as described in ‘Materials and Methods’. T0, T3, T10 and T21 indicate the
measurement performed before the treatment, and after 3 days, 10 days and 21
days from the beginning of the schedule, respectively. Bars, S.D.s. Inset, table
representing the P-values and the statistical signiﬁcance of the changes of the
different values
Figure 1 Modulation of intracellular levels of ROS. PBMC of 23 patients resistant to treatment (PD) and 20 patients responsive to treatment (SD) enrolled in the So.LAR
studywereincubatedwithdihydroethidineandanalyzedbyFACSasdescribedin‘MaterialsandMethods’.(a)RepresentationoftheROSlevelsexpressedasthepercentage
of MFI derived by dihydroethidine oxidation of 43 patients. T0, T3, T10 and T21 indicate the time of sample collection before the treatment and after 3 days, 10 days and 21
daysfromthebeginningoftheschedule,respectively.Bars,S.D.s.(bandc)FlowcytometricanalysisofPBMCofaresistantandaresponsivepatient,respectively,exposedto
dihydroethidine used as a probe for measurement of O2
  at different times of treatment. CTR , PBMC not labeled; T0, T3, T10, T21 indicate the measurement performed
before the treatment, and after 3 days, 10 days and 21 days from the beginning of the schedule, respectively. Inset, table representing the P-values and the statistical
signiﬁcance of the changes of the different values
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Cell Death and Diseasetarget of sorafenib and then a marker of biological activity of
the drug.
Therefore, we have evaluated the activation status of
Erk1/2 in the PBMC of 17 resistant and 15 sensitive patients,
with both western blotting and FACS analysis for pERK-1/2 in
PBMCs. The results obtained with the two techniques were
absolutely overlapping.
We have found a gradual reduction of Erk1/2 activity in SD
patients reaching a maximal decrease of 50% after 21 days
(T21) from the beginning of therapy (Figure 4a). On the other
hand, Erk1/2 activity was only about 10% reduced after
10 days (T10) of treatment with sorafenib alone (Po0.05). On
the other hand, in resistant patients, the Erk1/2 activity was
about 80% increased after 21 days (T21) from the beginning
oftherapy.This increasewasdetectedalsoafter10daysfrom
the beginning of therapy with sorafenib alone, but the change
was again not statistically signiﬁcant (P40.05). The trend of
Erk1/2 activity was conﬁrmed by the analysis of 20 patients
through western blotting analysis. In Figure 4b, western
blotting for pERK1/2 in a responder and a resistant patient,
respectively, are shown. The results clearly suggest the
inverse trend of pERK1/2 in the two patients.
In conclusion, the addition of octreotide LAR did not
interfere with the biological effects induced by sorafenib and
evenincreasedthe effectsofsorafenib inresponsive patients.
The phosphorylation of Erk can be a surrogate marker of
sorafenibþoctreotide activity if evaluated after 21 days from
the beginning of the treatment (cut-off: 21MFI). Moreover, the
detection of pERK at FACS was a valid assay for the
evaluation of pERK intracellular levels.
Discussion
The activation of Ras-MAPK-dependent pathway has a key
role in the genesis and progression of human HCC.
27–29 This
signaling pathway, found in all proliferative cells, determines
theactivationofErkproteinbyitsphosphorylationthatfavours
the HCC progression and promotes the tumor growth and
angiogenesis. In fact, it was demonstrated a progressive and
aberrant Erk1/2 activation in the tumor liver tissue compared
withthenormalcounterpart,withamorepronouncedincrease
in tumors with poor prognosis, without mutations of Ras
protein. Mutations of Ras, Raf and EGFR genes, that both
activate the Ras-MAPK-dependent pathway, are very rare
in human HCC.
27–29 However, studies on mutations of Raf
familygenesinsigniﬁcantlywideseriesarenotavailableinthe
literature.
30 The development of HCC is closely related to
angiogenesis and to disruption of liver vascular architecture,
which contributes both to increased hepatic vascular resis-
tance and portal hypertension. On the other hand, it was
recently reported that angiogenesis modulates the formation
of portal-systemic collaterals and the increased splanchnic
blood ﬂow, which are involved in the life threatening
complications of cirrhosis. Finally, angiogenesis has a key
role in the growth of tumors, suggesting that interference with
angiogenesis may prevent or antagonize the development of
HCC.
31 Moreover, VEGF levels in HCC tissues correlated to
the recurrence of HCC after hepatectomy.
32
Sorafenib is a multikinase inhibitor able to antagonize
differentmolecularmechanismsinvolvedintheprogressionof
HCC inhibiting both Raf and VEGF-R. Octreotide is also able
to inhibit angiogenesis and is an effective agent in improving
the QoL of patients affected by HCC.
24 Important topics in the
ﬁeld of target-based therapy of human tumors including HCC
is represented by the need of predicting the response of the
patients to the treatment in order to both avoid unuseful side
effects and to limit the cost of the therapy. At least, at our
knowledge,up-to-datereportsondeﬁnitivepredictivemarkers
of response to octreotide are not still available. On the other
Figure 4 Modulation of Erk1/2 activity. PBMC of 17 patients resistant to
treatment (PD) and 15 patients responsive to the treatment (SD) enrolled in the
So.LAR study were processed for the evaluation of the intracytoplasmic expression
of Erk 1/2 activity. (a) Representation of the percentage of pERK1/2 levels
compared with PBMC labeled with a speciﬁc antibody obtained by cytoﬂuorimetric
analysis of indirectly-labeled PBMC of 32 patients. (b) Detection of phosphorylation
levels of Erk1/2 evaluated by western blot analysis as described in ‘Materials and
Methods’. T0, T3, T10 and T21 indicate the measurement performed before the
treatment, and after 3 days, 10 days and 21 days from the beginning of the
schedule, respectively. Bars, S.D.s. Inset, table representing the P-values and the
statistical signiﬁcance of the changes of the different values
Figure 3 Modulation of serum levels of NO. Variations of NO serum levels in
23 patients resistant to treatment (PD) and 20 patients responsive to the treatment
(SD) enrolled in the So.LAR study, using an enzyme spectrophotometric assay as
described in ‘Materials and Methods’. T0, T3, T10 and T21 indicate the
measurement performed before the treatment, and after 3 days, 10 days and 21
days from the beginning of the schedule, respectively. Bars, S.D.s. Inset, table
representing the P-values and the statistical signiﬁcance of the changes of the
different values
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Cell Death and Diseasehand, it has been recently demonstrated that the phosphor-
ylation levels of Erk in the tumor tissues correlated with the
time to progression of patients affected by HCC.
32 Zhang and
colleagues
17 conﬁrmed that Erk phosphorylation is a potential
surrogate marker of sorafenib activity in human HCC cell
lines. It is also possible to evaluate the effects of sorafenib on
PBMC, where the pERK activity levels were correlated with
oxidative stress induced by Vibrio vulniﬁcus.
33 However, non-
invasive methods for the determination of Erk activity during
the treatment are strongly warranted. In this view, quick, easy
and quantitative methods for the ex vivo determination of
pERK in PBMC have been developed on the basis of
cytoﬂuorimetric techniques.
34 On these basis, we have
evaluated the effects of So.LAR treatment on Erk activity in
PBMC of patients affected by HCC with cytoﬂuorimetric
technique.
Ourresultshaveconﬁrmedtheabsoluteoverlappingofdata
obtained by FACS and those determined with western
blotting, suggesting the feasibility of molecular screening
studies on biological agents through the determination of
pERK in the PBMC. Our data suggested that the treatment
with octreotide LAR did not change the effects of sorafenib on
Erk phosphorylation. In fact, in resistant patients, pERK levels
increasedalreadybeforetheadministrationofoctreotideLAR.
This effect can be likely induced by the triggering of a feed-
back pathway activated by the sorafenib-mediated inhibition
of Raf kinase that can elicit alternative modes of Mek
activation that, in turn, causes Erk phosphorylation. In fact,
protein kinase C alpha can trigger Ras and Raf-independent
Mek/Erk activation in human hepatoma cell HepG2
35 and
cannot be excluded, that also in PBMNC alternative
Erk-activation pathway exist in speciﬁc patients. On the other
hand, in sensitive patients, the decrease of pERK levels
detected at day 10 (T10) was potentiated by the addition of
octreotide LAR (T21). These results demonstrated, at least in
our series of patients, the absence of a pharmaco-dynamic
interaction between the two agents, suggesting the chance to
use them in combination in the HCC treatment.
It is known that anti-oxidative enzymes, such as CAT and
SOD are signiﬁcantly downregulated in HCC, because of a
gene re-organization to support the proliferating ability of
tumor cells. In fact, cancer cells carry out different survival
mechanisms to increase their proliferative ability and the
presence of ROS has a pivotal role in these processes.
Moreover, cancer cells escape from apoptosis induced by
excessive levels of ROS activating both Erk e PI3K signal
transduction pathways.
Onthesebases,wehaveevaluatedthelevelsofROSinthe
PBMC of patients treated with So.LAR schedule by cytoﬂuori-
metric analysis based on incubation of PBMC with dihydro-
ethidine, which is oxidized in cells to ﬂuorescent ethidium
bromide in the presence of superoxide anions.
We have found a signiﬁcant increase of ROS levels after
10 days (T10) from the beginning of the treatment that
continues to go up also after 21 days (T21) of treatment in the
resistant patients. On the other hand, in the sensitive patients,
there was a gradual decrease of ROS levels that reached the
maximal effect after 21 days from the beginning of the
treatment. These effects were paralleled by the regulation of
serum activity of SOD that was unchanged in resistant
patients, whereas gradually increased in sensitive patients
after 21 days from the beginning of the treatment. These data
suggest once again the absence of pharmaco-dynamic
interaction between the two agents and the possible use of
oxidative stress levels as predictor markers of clinical
outcome to this treatment.
In cancerbiology, NOcanbe involved eitherinpromotion or
in prevention of tumor occurrence dependently from tumor
microenvironment, NO concentration and time of exposure.
NO is a product of endothelial cells that binds and activates
the guanylatecyclase,whichcatalyzesthe conversionofGTP
to the second messenger molecule cyclic GMP. Concentra-
tions of NO ranging between 1 and 30nM produce high levels
of cyclic GMP, promoting angiogenesis and proliferation of
endothelial cells. In these conditions, Erk phosphorylation
stimulates the proliferation of endothelial cells. Concentra-
tions of NO ranging between 30 and 100nM correspond to
an increase of proliferative and anti-apoptotic Akt and
Erk-dependent pathways in tumor cells.
36,37 This range of
concentrations seems to protect tumor cells from apoptosis
and enhance angiogenic effects. In these conditions, the
molecules activated by NO can be considered as factors
correlatedtopoorprognosisevents.Ontheotherhand,higher
NO levels (4300nM) promote apoptosis and are responsible
for anti-tumor activity. NO levels are inﬂuenced also by ROS,
in particular by superoxide anions that can attenuate the NO-
mediated pathway. In fact, superoxide anion and ROS,
through the scavenging of NO, can lower NO levels favouring
its tumor-promoting activity.
38 Usually, tumors have high
levels of ROS and low levels of SOD.
In this study, we have evaluated, using a spectrophoto-
metric assay, serum NO levels of patients treated with
So.LAR schedule. After 3 days (T3) from the beginning of
the treatment, resistant patients presented a strong increase
of NO levels that resumed to basal levels at day 10 and
thereafter. On the other hand, in sensitive patients NO levels
increased at T3 and remained elevated during all the
pharmacological treatment.
These data indicate that the trend of NO activity is
correlated with the prognosis of HCC patients treated with
So.LAR schedule. In fact, in sensitive patients, the increased
levels of NO probably had an anti-tumor and pro-apoptotic
role, as demonstrated by the decrease of Erk activation. On
the other hand, resistant patients presented low levels of NO
correlated to the induction of Erk activation. Also in this case,
the addition of octreotide LAR to sorafenib did not interfere
with the biological and biochemical effects of the latter, and in
some cases octreotide LAR even potentiated the effects of
sorefenib.
Inconclusion,thecombinationusedinSo.LARrepresentsa
valid approach in the treatment of patients affected
by advanced HCC. However, the treatment of the patients
with the combination induces also important side effects and
has a relevant cost. Therefore, the possibility to select the
sensitive patients on the basis of easy-to-detect clinical and
molecular markers has a high clinical impact. The determina-
tion of both pERK expression in PBMC with FACS analysis
and the oxidative stress status have high value in the
prediction of response to sorafenibþoctreotide therapy in
HCC patients.
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Cell Death and DiseaseMaterials and Methods
Patient characteristics, treatment schedule and isolation of
peripheral blood mononuclear cells (PBMC). A total of 50 patients
(43 M/7 F) were enrolled between July 2007 and July 2008. Patients were required
to have HCC conﬁrmed by biopsy or diagnosed by radiological and clinical criteria,
as previously described.
27 Patients received sorafenib 400mg bid for 28 days, with
afollowingweekofrestandlong-actingoctreotideatadoseof40mgevery28days.
Treatment was continued until disease progression or unacceptable toxicity. The
ﬁrstoctreotideinjectionwasadministered10daysaftersorafenib,startinginorderto
evaluate eventual pharmcodynamic interference between the two agents. Dose
reduction of sorafenib (200mg bid) and octreotide (20mg) were allowed for drug-
related toxicities (National Cancer Institute Common Toxicity Criteria version 2.0).
Response to treatment was assessed by at least two independent radiologists,
using RECIST criteria every 2 months. Patients were considered ‘responsive to the
treatment’ if a PR or a SD lasting equal or more than 6 months was recorded and
‘resistant to treatment’ if a PR or SD lasting less than 6 months or a PD was
recorded. The biological samples (both sera and PBMC) were collected before the
treatment (T0), and before 3 days (T3), 10 days (T10) and 21 days (T21) from the
beginning of the schedule.
PBMC were isolated from freshly obtained blood by FICOLL density gradient
centrifugation, as previously described.
39 PBMC were stored at  801C for all the
following experiments. Sera were collected from the patients at the selected times
and stored at  201C for all the following experiments.
Cytoﬂuorimetric analysis of oxidative stress. PBMC of patients were
incubated with dihydroethidine (20ng/ml for 1h) and analyzed by FACScan ﬂow
cytometer (FacSCAN, Becton Dickinson, San Jose `, CA USA). For each sample,
about 20000 events were acquired and the ﬂuorescence was measured on FL2-H
channel by the FACScalibur (Applied Biosystems, Carlsbad, CA, USA) software.
The MFI indicates ROS (O
2 ) levels.
SOD assay. SOD are metalloenzymes that catalyze the dismutation of
superoxide radical into hydrogen peroxide (H2O2)þmolecular oxygen (O2) and
consequently provide an important protection mechanism against superoxide
radical toxicity.
To determine SOD activity, we have applied the xanthine/xanthine oxidase
(XOD)system to generatesuperoxideanionsand a chromogen to producea water-
soluble formazan dye upon reduction by superoxide anions. The rate of the
reduction with O2
  is linearly related to the xanthine oxidase (XO) activity, and is
inhibited by SOD. Therefore, the IC50 (50% inhibition activity of SOD) can be
determined by this colorimetric method. Absorbance can be measured at 440nm.
Spectrophotometric determination of NO serum levels. The
determination of serum NO concentration, expressed in mM, has been performed
with an indirect method through the measure of serum concentrations of nitrates
and nitrites. For NO determination, the spectrophotometric reaction of Griess
was used.
40
Cytoﬂuorimetric analysis of Erk activity. The PBMCs were ﬁxed with
3% paraformaldehyde in PBS for 30min at room temperature and permeabilized
with 0.5% Tween 20 in PBS for 5min. The PBMCs were exposed to a speciﬁc
antibody, directly against pMAPK p42/44 (10mg/ml per sample) for 30min at 41C,
and then incubated with FITC-conjugated anti-mouse goat antiserum (25ml per
sample) for 30min at 41C. After ﬁnal washes, samples were analyzed by FACScan
ﬂow cytometer (FACScan, Becton Dickinson, Mountain View, CA, USA). For each
sample,about20000eventswereacquiredandtheﬂuorescencewasmeasuredon
FL2-H channel by the FACScalibur (Applied Biosystems) software.
Determination of Erk activity by immunoblotting. The PBMC were
lysed for 30min at 41C in lysis buffer (1% Triton, 0.5% sodium deoxycholate, 0.1
NaCl, 1mM EDTA, pH 7.5, 10mM Na2HPO4, pH 7.4, 10mM PMSF, 25mM
benzamidine, 1mM leupeptin, 0.025 units per ml aprotinin). About 100mgo f
proteins were incubated with a speciﬁc antibody directed against pMAPK p42/44
and immunoprecipitated with Protein A sepharose.
41 Proteins were run on SDS-
PAGE, transferred on nitrocellulose ﬁlm and incubated with the same primary
antibody. Films were developed using the chemoluminescence assay (SuperSignal
West Pico, Pierce, Rockford, IL, USA).
Determinationofcut-offvalue. Thismethodforchoosingacut-offisbased
on the application of 95% CI of mean. Mean and standard deviation (S.D.) of trial
valuesare calculated. Theinterval obtained by subtracting2 S.D. frommean and by
adding2 S.D.tomean(thatis,m±2s)showsthatthechanceofatrialvaluecoming
outside this interval will be less than 5%. The lower limit of this interval (i.e.
mean 2S.D.) may be considered as cut-off point. If a subject’s trial value comes less
than this cut-off, then it may be considered negative (normal), and if value comes
greater than or equal to cut-off value, then it is considered positive (diseased).
Statistical analysis. All data are expressed as mean±S.D. Statistical
analysis was performed by analysis of variance (ANOVA) with Neumann–Keul’s
multiplecomparisontest orKolmogorov–Smirnov,where appropriate. Theasterisks
in the ﬁgure indicate signiﬁcant difference between the basal patient with respect to
the patients treated with SO.LAR therapy (**Po0.003; *Po0.05; n.s., not
signiﬁcant). The differences between patients with PD and those with SD were
performed using the Mann–Whitney U-test for non-parametric independent and
continuous variables.
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